Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists

Author:

Sellers Rani S.1ORCID,Nelson Keith2,Bennet Bindu3,Wolf Jayanthi4,Tripathi Niraj5,Chamanza Ronnie6ORCID,Perron Lepage Marie-France7,Adkins Karissa8,Laurent Sebastien9,Troth Sean P.4ORCID

Affiliation:

1. Pfizer Inc, Pearl River, New York, NY, USA

2. Charles River Laboratories, Mattawan, MI, USA

3. Janssen Research & Development LLC, Spring House, PA, USA

4. Merck & Co, Inc, West Point, PA, USA

5. Covance, Madison, WI, USA

6. Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium

7. Charles River Laboratories, St-Germain-Nuelles, France

8. Sanofi US, Framingham, MA, USA

9. Sanofi R&D, Preclinical Safety Department, Montpellier, France

Abstract

The design and execution of toxicology studies supporting vaccine development have some unique considerations relative to those supporting traditional small molecules and biologics. A working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee conducted a review of the scientific, technical, and regulatory considerations for veterinary pathologists and toxicologists related to the design and evaluation of regulatory toxicology studies supporting vaccine clinical trials. Much of the information in this document focuses on the development of prophylactic vaccines for infectious agents. Many of these considerations also apply to therapeutic vaccine development (such as vaccines directed against cancer epitopes); important differences will be identified in various sections as appropriate. The topics addressed in this Points to Consider article include regulatory guidelines for nonclinical vaccine studies, study design (including species selection), technical considerations in dosing and injection site collection, study end point evaluation, and data interpretation. The intent of this publication is to share learnings related to nonclinical studies to support vaccine development to help others as they move into this therapeutic area. [Box: see text]

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Reference92 articles.

1. Therapeutic Cancer Vaccines

2. Efficacy and Safety of the Immunization with DNA for Alzheimer’s Disease in Animal Models: A Systematic Review from Literature

3. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles

4. European Medicines Agency. Note for guidance on preclinical pharmacological and toxicological testing of vaccines. 1997. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-preclinical-pharmacological-toxicological-testing-vaccines_en.pdf. Accessed March 15, 2019.

5. World Health Organization. Annex 1. Guidelines on the Nonclinical Evaluation of Vaccines. Geneva, Switzerland: World Health Organization; 2005:31–63.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3